Amendments to the Claims:

The listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

Claims 1-15 (Canceled)

Claim 16 (Currently Amended): A formulation consisting essentially of

at least one EFA selected from the group consisting of: gamma-linolenic acid; dihomogammalinolenic acid; arachidonic acid; adrenic acid; docosapentaenoic acid; stearidonic acid; eicosatetraenoic acid (n–3); eicosapentaenoic acid; docosapentaenoic acid (n–3) and docosahexaenoic acid,

at least one homocysteine-lowering agent selected from the group consisting of: vitamin B12; folic acid, at a maximum daily dose of 5 mg; and vitamin B6, at a maximum daily dose of 20 mg; and

optionally at least one antioxidant.

Claim 17 (Previously Amended): The formulation of claim 16, wherein the formulation is a pharmaceutical formulation.

Claim 18 (Original): The formulation of claim 16, wherein the formulation is a nutritional formulation.

Claim 19 (Original): The formulation of claim 16, wherein the formulation is in the form of a hard gelatin capsule or a soft gelatin capsule.

Claim 20 (Canceled)

Claim 21 (Previously Presented): The formulation of claim 16, wherein the homocysteine-lowering agent is present in an amount of at least 200 μg.

Claim 22 (Previously Presented): The formulation of claim 16, wherein the homocysteine-lowering agent is 5 mg of vitamin B12.

Claim 23 (Original) The formulation of claim 16, wherein the at least one EFA is a eicosapentaenoic acid (EPA).

Claim 24 (Original): The formulation of claim 23, wherein the eicosapentaenoic acid (EPA) is the ethyl ester form or the pure tri-EPA triglyceride form.

Claim 25 (Original): The formulation of claim 16, wherein the EFA is arachidonic acid.

Claim 26 (Original): The formulation of claim 16, wherein the EFA is gammalinolenic acid or dihomogammalinolenic acid.

Claim 27 (Original): The formulation of claim 16, wherein the EFA is docosahexaenoic acid.

Claim 28 (Previously Presented): The formulation of claim 16, wherein two or more EFAs are present.

Claim 29 (Previously Presented): The formulation of claim 16, wherein the EFA is at least 5% of the formulation.

Claim 30 (Previously Presented): The formulation of claim 16, wherein the EFA is 15% or more of the formulation.

Claim 31 (Previously Presented): The formulation of claim 16, wherein the EFA is 30% or more of the formulation.

Claim 32 (Previously Presented): The formulation of claim 16, wherein the EFA is 50% or more of the formulation.

Claim 33 (Previously Presented): The formulation of claim 16, wherein the EFA is 90% or more of the formulation.

Claim 34 (Previously Presented): The formulation of claim 16, wherein the EFA is 95% or more of the formulation.

Claim 35 (Original): The formulation of claim 16, wherein vitamin B12 is the only homocysteine-lowering agent.

Claim 36 (Original): The formulation of claim 35, wherein vitamin B12 is in the form of hydroxocobalamin.

Claim 37 (Previously Presented): The formulation of claim 16, wherein folic acid is the only homocysteine-lowering agent.

Claim 38 (Original): The formulation of claim 16, wherein the formulation is in a form suitable for oral administration.

Claim 39 (Original): The formulation of claim 16, wherein the antioxidant is selected from the group consisting of: natural, synthetic or semi-synthetic vitamin E; natural, synthetic or semi-synthetic coenzyme Q; natural, synthetic or semi-synthetic alpha-lipoic acid; and natural, synthetic or semi-synthetic vitamin C.

Claims 40-41 (Canceled)

Claim 42 (Original): The formulation of claim 16, wherein the EFA is in the form of a natural oil.

Claim 43 (Canceled)

Claim 44 (Previously Presented): A method of treating a subject in need of homocysteine-lowering therapy which comprises administering to the subject the formulation of claim 16.

Claim 45 (Previously Presented): A method of treating a subject in need of homocysteine-lowering therapy which comprises administering to the subject the formulation of claim 24.

Claim 46 (Previously Presented): The method of claim 44, wherein the subject suffers from one or more of the following conditions:

(a) a cardiovascular disorder; a cerebrovascular disorder; atherosclerosis; heart disease;

cerebrovascular disease; stroke; peripheral vascular disease; thrombosis;

(b) diabetes; pre-diabetes (syndrome X); macrovascular complications of diabetes; microvascular complications of diabetes; cardiovascular disease; retinopathy; nephropathy; neuropathy;

(c) a psychiatric disorder; schizophrenia; a schizotypal disorder; a schizophreni form disorder; bipolar disorder (mania, or manic depression); depression; a panic disorder; an anxiety disorder; a sleep disorder; a social phobia;

(d) a neurological disorder; a neurodegenerative disorder; Alzheimer's disease; dementia; Parkinson's disease; multiple sclerosis; Huntington's disease; chronic pain;

(e) a kidney disorder;

(f) an inflammatory or an immunological disorder of the gastrointestinal tract, the respiratory system, the skin and mucous membranes, or the joints or other tissues;

(g) an eye or hearing disorder; age-related macular degeneration; age-related deafness; tinnitus;

(h) obesity; or

(I) cancer.

Claim 47 (Previously Presented): The method of claim 45, wherein the subject suffers from one or more of the following conditions:

(a) a cardiovascular disorder; a cerebrovascular disorder; atherosclerosis; heart disease; cerebrovascular disease; stroke; peripheral vascular disease; thrombosis;

(b) diabetes; pre-diabetes (syndrome X); macrovascular complications of diabetes;

microvascular complications of diabetes; cardiovascular disease; retinopathy; nephropathy; neuropathy;

(c) a psychiatric disorder; schizophrenia; a schizotypal disorder; a schizophreni form disorder; bipolar disorder (mania, or manic depression); depression; a panic disorder; an anxiety disorder; a sleep disorder; a social phobia;

(d) a neurological disorder; a neurodegenerative disorder; Alzheimer's disease; dementia; Parkinson's disease; multiple sclerosis; Huntington's disease; chronic pain;

(e) a kidney disorder;

(f) an inflammatory or an immunological disorder of the gastrointestinal tract, the respiratory system, the skin and mucous membranes, or the joints or other tissues;

(g) an eye or hearing disorder; age-related macular degeneration; age-related deafness; tinnitus;

(h) obesity; or

(I) cancer.

Claim 48 (New): The formulation of claim 16, wherein the vitamin B12 is at a maximum daily dose of 5 mg.